spacer
home > ebr > autumn 2017 > unleashing 3d
PUBLICATIONS
European Biopharmaceutical Review

Unleashing 3D

The last 10 years have seen a dramatic surge in the number of publications about organoids – but what are they and why is everyone talking about them? In simple terms, they are miniature organs grown in vitro in a near-physiological 3D environment. Unlike simple tissue cultures, they retain features of the organ they are derived from, including important structural and functional properties, and many believe that they could dramatically accelerate the understanding of human biology and disease progression.

Traditional 2D cell culture has brought great progress in understanding human development over the last 50 years. However, studying organogenesis in vitro has been hindered by the lack of appropriate systems that would allow the cell-to-cell interactions needed for organ formation. Organoids provide the accurate and physiologically relevant models that are needed to overcome this deficiency.

So-called organoids have now been derived from gut, kidney, pancreas, liver and brain tissue, and growing these mini-organs has been made possible by the recent advances in stem cell systems and the development of 3D support matrices. Thanks to this new technology, cells derived from stem cells or organ progenitors can self-organise through cell sorting and recapitulate the complexity of mammalian organogenesis in vitro in a way that is similar to how they do in vivo.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Colin Sanctuary is a biomedical engineer and Chief Executive Officer at QGel. Following his PhD in biomedical engineering at École Polytechnique Fédérale de Lausanne, Switzerland, Colin worked in product development and later in global marketing in the medical device and pharma industries. In 2009, he co-founded QGel with the aim of building a company that contributes to improving R&D productivity in pharma, particularly in the area of developing novel anticancer treatments.
spacer
Dr Colin Sanctuary
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Perfect Gx Elite vials presented by Gerresheimer at CPhI Worldwide

Düsseldorf/Frankfurt, October 24, 2017. The Gx Elite vials have set new standards for type 1 borosilicate glass vials. They are the result of comprehensive optimization measures in the conversion process, which have focused on designing out the risk to create product flaws during production including the removal of all glass-to-glass contact beginning with the tubing material all the way through final packaging. The chemical composition of the borosilicate glass is still the same. Gerresheimer will be showcasing Gx Elite vials at booth D02 in Hall 4.2 at CPhI Worldwide in Frankfurt (Germany) from October 24 to 26, 2017.
More info >>

White Papers

Advances in Aseptic Blow-Fill-Seal Processing of Pharmaceutical Liquids Improve Product Integrity and Patient Safety

Weiler Engineering, Inc

The latest improvements in aseptic blow-fill-seal technology are providing more streamlined automation of critical B/F/S processing areas, while limiting human intervention and effectively reducing airborne microbial bioburden and particulate levels, and enhancing sterility assurance and patient safety.
More info >>

 
Industry Events

5th Biennial Biosimilars & Biobetters Congress 2018

16-17 April 2018, Novotel London West Hotel, Hammersmith, London

Oxford Global are proud to present our highly anticipated 5thBiennial Biosimilars & Biobetters Congress, 16th – 17thApril 2018, London, UK. Over 450 proteins, peptides and biosimilars delegates representing leading biotech companies, global pharmaceutical organisations and internationally renowned academic institutions will enjoy over 20 presentations and case studies focusing on the key areas of the biosimilars industry including market access strategies, clinical development, commercialisation, manufacturing and bio-analytics
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement